Mabylon develops monoclonal antibodies, including MY012, which targets the inflammasome pathway. It is leading the Eurostars ASCEND project, worth EUR 1.46 million, to advance this candidate against inflammatory bowel disease.
- Announced on
- Round
- Grant
- Amount
- Amount not disclosed
- Location
- canton of Zurich
- Sector
- Biotech & life sciences
Investors
- Eurostars lead
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic